Anticoagulation

Anticoagulation is the physiological process or therapeutic intervention used to inhibit blood clot formation and maintain vascular patency (StatPearls: NBK537021). It is not a single molecular target but rather a pharmacological state achieved by modulating the coagulation cascade, a series of enzymatic reactions involving proteins such as Factor Xa and Thrombin (Factor IIa) (NIH: Blood Thinners). Clinically, anticoagulation is fundamental for the prevention and treatment of thromboembolic conditions, including deep vein thrombosis, pulmonary embolism, and stroke in patients with atrial fibrillation (PubMed: PMID 31191048). Therapeutic agents range from traditional vitamin K antagonists to modern direct oral anticoagulants (DOACs) that offer more targeted inhibition of specific clotting factors (Wikipedia: Anticoagulant). The primary clinical challenge associated with anticoagulation is balancing the prevention of thrombosis against the inherent risk of life-threatening hemorrhage (PubMed: PMID 30204555). Consequently, effective therapy often requires careful patient selection, monitoring of coagulation parameters, and awareness of potential drug interactions.

Other names

Blood thinningAntithrombotic therapyCoagulation inhibitionAnticoagulant effect

Anticoagulation is a therapeutic effect achieved by interfering with the blood coagulation cascade through various mechanisms: the inhibition of Vitamin K epoxide reductase (e.g., Warfarin), the potentiation of antithrombin III (e.g., Heparin), the direct inhibition of Factor Xa (e.g., Apixaban, Rivaroxaban), or the direct inhibition of Thrombin/Factor IIa (e.g., Dabigatran) [StatPearls: NBK537021, NIH: Blood Thinners].